← SynDRA
CERITINIB
SynDRA canonical compound SYN0037441 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ALK |
|---|
| Mechanism of action | ALK inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- ALK
- TSSK1B
- INSR
- IGF1R
- FLT3
- ABCB1
- PLK4
- MAPK7
- MET
- MKNK2
- NTRK1
- NTRK2
Mechanisms of action (all sources)
- ALK INHIBITOR
- ALK tyrosine kinase receptor inhibitor
- FLT3 INHIBITOR
- IGF1R INHIBITOR
- INSR INHIBITOR
- TSSK1B INHIBITOR
- ALK MODULATOR
Drug classes
- Tyrosine Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 2C9 Inhibitors
- Cytochrome P450 3A Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- NVP-LDK378-NX
- zykadia
- LDK378
- CERITINIB[MI]
- 4MK
- CERITINIB (LDK378)
- CPD 15
- LDK-378
- NVP-LDK-378-NX
- Zykadia
- ZYKADIA
- LDK 378
- UNII-K418KG2GET
- LDK378(Ceritinib)
- Eritinib (LDK378)
- 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
- K418KG2GET
- CHEMBL2403108
- CHEBI:78432
- AK174337
- C28H36ClN5O3S
- 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine
- 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim
- ceritinibum
- RefChem:57924
- DTXCID50676118
- L01XE28
- Ceritinib (LDK378)
- MFCD26142648
- Ceritinib(LDK378)
- Ceritinib [USAN:INN]
- Ceritinib[mi]
- Zykadia (TN)
- Ceritinib (Standard)
- Ceritinib; LDK378
- CERITINIB [INN]
- CERITINIB [JAN]
- CERITINIB [MI]
Reported adverse events
- Abdominal pain
- Bradycardia
- Constipation
- Fatigue
- Hepatotoxicity
- Interstitial lung disease
- Nausea
- Pancreatitis
- Pericarditis
- Pneumonitis
- Rash
- Vomiting
Look up CERITINIB in the interactive SynDRA portal →